I-Mab (NASDAQ:IMAB) Short Interest Update

I-Mab (NASDAQ:IMAB) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 685,600 shares, an increase of 13.5% from the November 30th total of 604,100 shares. Based on an average daily trading volume, of 469,300 shares, the days-to-cover ratio is currently 1.5 days.

Institutional Trading of I-Mab

A number of institutional investors have recently bought and sold shares of IMAB. Caligan Partners LP raised its position in shares of I-Mab by 3.7% in the third quarter. Caligan Partners LP now owns 3,499,330 shares of the company’s stock valued at $4,339,000 after buying an additional 124,539 shares in the last quarter. Bank of Montreal Can bought a new position in I-Mab during the 2nd quarter worth $453,000. Garden State Investment Advisory Services LLC acquired a new position in I-Mab in the 3rd quarter valued at $179,000. Finally, XTX Topco Ltd lifted its position in shares of I-Mab by 140.8% during the 3rd quarter. XTX Topco Ltd now owns 43,039 shares of the company’s stock valued at $53,000 after acquiring an additional 25,163 shares during the period. Institutional investors own 38.38% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of I-Mab in a report on Friday, November 15th.

I-Mab Trading Down 3.4 %

NASDAQ:IMAB traded down $0.03 during mid-day trading on Wednesday, hitting $0.85. The company had a trading volume of 392,844 shares, compared to its average volume of 357,170. I-Mab has a fifty-two week low of $0.84 and a fifty-two week high of $2.54. The business’s fifty day moving average is $1.02 and its two-hundred day moving average is $1.22.

I-Mab Company Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.